Progress in Clinical Trial Research on Lecanemab for the Treatment of Alzheimer's Disease
Abstract：Alzheimer's disease (AD) is the most common cognitive dysfunction in the elderly. It has an insidious onset, with early symptoms including memory impairment. As the disease progresses, language, psychiatric behavioral, and social function impairments may occur, ultimately leading to an inability to be self-reliant, placing a significant burden on patients and their families [1-3]. The pathogenesis of AD includes excessive accumulation of beta-amyloid peptide (Aβ), abnormal phosphorylation of tau protein, reduction of cholinergic neurons, neuroinflammation, mitochondrial dysfunction, and oxidative stress. In recent years, disease-modifying therapies have made some progress [4]. Lecanemab, as an anti-Aβ drug, has shown potential in clinical trials to slow the progression of AD [5]. This review will elaborate on the progress of clinical trials of lecanemab in the treatment of AD.
Keywords：Alzheimer's diseaseAmyloid beta peptidesClinical trialsLecanemab
Publication Date：2025-06-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 822-823 )